Pomalidomide NDC 0480-4018

NDC codes

FDA NDC Directory

Product NDC (as listed)0480-4018Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00480-4018Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0480-4018-21	00480401821	21 CAPSULE in 1 BOTTLE (0480-4018-21)Marketed from Mar 2, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pomalidomide
Generic name (nonproprietary): pomalidomide
Active ingredients: Pomalidomide — 1 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Teva Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209956
Marketing start: Mar 2, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 0480-4018_35c82741-852e-4c33-ab34-02eb6b9aa318SPL ID 35c82741-852e-4c33-ab34-02eb6b9aa318SPL set ID dee932c5-0c7c-45f0-b2bb-c027badee537RxCUI 1369718, 1369726, 1369730, 1369734UNII D2UX06XLB5UPC 0304802601213, 0304804035214, 0304804018217, 0304804022214
Pharmacologic class: Thalidomide Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400480401821 followed by a unit qualifier and the quantity

Package 00480-4018-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 1, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Pomalidomide is a thalidomide analogue indicated for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical b…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209956

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209956
Product	Strength	Form · route	Labeler	Product NDC
Pomalidomide	Pomalidomide 2 mg/1	CapsuleOral	Teva Pharmaceuticals, Inc.	0480-4022
Pomalidomide	Pomalidomide 4 mg/1	CapsuleOral	Teva Pharmaceuticals, Inc.	0480-4035
Pomalidomide	Pomalidomide 3 mg/1	CapsuleOral	Teva Pharmaceuticals, Inc.	0480-2601